Navigation Links
MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
Date:9/10/2007

VANCOUVER and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will present results of viral resistance studies with its anti-HCV agent celgosivir at the 14th International Symposium on Hepatitis C Virus and Related Viruses (http://www.hcv2007.com) being held September 9th to 13th 2007 in Glasgow, Scotland.

The presentation entitled: "Celgosivir (MX-3253) Resistance Profile Using Bovine Viral Diarrhea Virus" will be made today from 5:30pm to 8:00pm, Glasgow time (9:30am - noon Pacific Time) by Dominique Dugourd, Ph.D., Microbiology Group Leader at MIGENIX. A copy of the presentation and the related Abstract (abstract P-223) will be available at http://www.migenix.com at the start of the presentation. The conference covers a broad spectrum of topics from molecular virology to new antiviral therapies and attracts major scientists and thought leaders in the field.

Jacob Clement, Ph.D., CSO at MIGENIX and coauthor of the paper, believes that the results of these laboratory studies with the accepted HCV surrogate virus BVDV, indicate that the emergence of resistance in a clinical setting is unlikely to occur. "We were unable to induce viral resistance to celgosivir even after repeated exposure to high levels of the agent in a system which rapidly develops relatively high levels of resistance to other direct acting antivirals."

About Celgosivir (MX-3253)

Celgosivir is an oral alpha-glucosidase I inhibitor and is currently the only anti-HCV drug in clinical development that acts on host-directed glycosylation. In preclinical studies, celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without ribavirin) and other drugs in develo
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced its financial ... 2007., Replidyne reported a net loss of $16.9 million ... loss per basic and diluted common share,of $0.63 per share, ... per,basic and diluted common share, for the quarter ended December ...
... SCOTTSDALE, Ariz., Feb. 26 MedPredict Market Research,a ... has published a new report providing critical strategic ... in the market for Rheumatoid,Arthritis (RA) therapies., ... & Analysis:,Rheumatoid Arthritis Q1 2008, MedPredict,s global Thought ...
... Current Radlink Board Member ... Joins Team, ... hardware company that has emerged as an,innovative provider of medical imaging systems ... With nearly 30 years of experience, Dr. Julien is currently director ...
Cached Biology Technology:Replidyne Announces 2007 Fourth Quarter and Full Year Results 2Replidyne Announces 2007 Fourth Quarter and Full Year Results 3Replidyne Announces 2007 Fourth Quarter and Full Year Results 4Replidyne Announces 2007 Fourth Quarter and Full Year Results 5Replidyne Announces 2007 Fourth Quarter and Full Year Results 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 7Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report 2Renowned Radiologist Peter J. Julien, MD Named Radlink Chief Medical Officer 2
(Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
(Date:4/17/2014)... Stem cells in bone marrow need to produce hydrogen ... tissue, according to a new study from the Center ... of Dentistry of USC. , Professor Songtao Shi, principal ... sulfide produced by the cells governs the flow of ... cellular signals that results in osteogenesis, or the creation ...
(Date:4/17/2014)... This news release is available in German . ... fails to pay the protection money demanded of him, he ... are seldom required, however, as fear of the consequences is ... is observed in parasitic birds, which lay their eggs in ... egg out, the brood parasites take their revenge by destroying ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... Research to be presented at the upcoming annual ... Behavior (SSIB), the foremost society for research into all ... can become dependent on highly palatable foods and engage ... behaviors we observe in drug addicts and those with ...
... The continued growth of cropland and loss of ... the Midwest. A Great Lakes Bioenergy Research Center ... with increased crop pest abundance and insecticide use, ... crops. While the relationship between landscape simplification, ...
... cities can make a significant contribution to carbon storage and, ... authorities and gardeners planted and maintained more trees. The study, ... of Applied Ecology , is the first to quantify how ... of Europe. Using satellite data and information gathered by ...
Cached Biology News:Evidence for 'food addiction' in humans 2Landscape change leads to increased insecticide use in the Midwest 2Plants in cities are an underestimated carbon store 2
... Our Accumix standard is a new ... mode electrospray ionization mass spectrometry. Accumix ... broad mass range coverage for both tuning ... LCQ- and LTQ-MS) and Fourier transform mass ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: